Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2016 4
2017 7
2018 10
2019 12
2020 9
2021 13
2022 10
2023 9
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Results by year

Filters applied: . Clear all
Page 1
Leveraging Off-Target Reads in Panel Sequencing for Homologous Recombination Repair Deficiency Screening in Tumor.
Ball M, Ourailidis I, Kluck K, Menzel M, Kirchner M, Allgäuer M, Tay TKY, Schnecko F, Volckmar AL, Goldschmid H, Neuman O, Fröhling S, Schirmacher P, Budczies J, Stenzinger A, Kazdal D. Ball M, et al. Among authors: kirchner m. J Mol Diagn. 2024 Mar 22:S1525-1578(24)00060-6. doi: 10.1016/j.jmoldx.2024.02.008. Online ahead of print. J Mol Diagn. 2024. PMID: 38522840 Free article.
Genomic heterogeneity at baseline is associated with T790M resistance mutations in EGFR-mutated lung cancer treated with the first-/second-generation tyrosine kinase inhibitors.
Menzel M, Kirchner M, Kluck K, Ball M, Beck S, Allgäuer M, Assmann C, Schnorbach J, Volckmar AL, Tay TKY, Goldschmid H, Tan DS, Thomas M, Kazdal D, Budczies J, Stenzinger A, Christopoulos P. Menzel M, et al. Among authors: kirchner m. J Pathol Clin Res. 2024 Mar;10(2):e354. doi: 10.1002/cjp2.354. J Pathol Clin Res. 2024. PMID: 38284983 Free PMC article.
First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations.
Blasi M, Kuon J, Lüders H, Misch D, Kauffmann-Guerrero D, Hilbrandt M, Kazdal D, Falkenstern-Ge RF, Hackanson B, Dintner S, Faehling M, Kirchner M, Volckmar AL, Kopp HG, Allgäuer M, Grohé C, Tufman A, Reck M, Frost N, Stenzinger A, Thomas M, Christopoulos P. Blasi M, et al. Among authors: kirchner m. Eur J Cancer. 2024 Mar;199:113556. doi: 10.1016/j.ejca.2024.113556. Epub 2024 Jan 17. Eur J Cancer. 2024. PMID: 38271745 Free article.
Sarcomas With RAD51B Fusions Are Associated With a Heterogeneous Phenotype.
Chang HY, Dermawan J, Sharma A, Dickson B, Turashvili G, Torrence D, Nucci M, Chiang S, Oliva E, Kirchner M, Stenzinger A, Mechtersheimer G, Antonescu C. Chang HY, et al. Among authors: kirchner m. Mod Pathol. 2024 Feb;37(2):100402. doi: 10.1016/j.modpat.2023.100402. Epub 2023 Dec 21. Mod Pathol. 2024. PMID: 38141829
Digital Spatial Profiling Identifies the Tumor Periphery as a Highly Active Biological Niche in Clear Cell Renal Cell Carcinoma.
Schneider F, Kaczorowski A, Jurcic C, Kirchner M, Schwab C, Schütz V, Görtz M, Zschäbitz S, Jäger D, Stenzinger A, Hohenfellner M, Duensing S, Duensing A. Schneider F, et al. Among authors: kirchner m. Cancers (Basel). 2023 Oct 19;15(20):5050. doi: 10.3390/cancers15205050. Cancers (Basel). 2023. PMID: 37894418 Free PMC article.
Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial.
Pouyiourou M, Kraft BN, Wohlfromm T, Stahl M, Kubuschok B, Löffler H, Hacker UT, Hübner G, Weiss L, Bitzer M, Ernst T, Schütt P, Hielscher T, Delorme S, Kirchner M, Kazdal D, Ball M, Kluck K, Stenzinger A, Bochtler T, Krämer A. Pouyiourou M, et al. Among authors: kirchner m. Nat Commun. 2023 Oct 24;14(1):6761. doi: 10.1038/s41467-023-42400-5. Nat Commun. 2023. PMID: 37875494 Free PMC article. Clinical Trial.
Multicentric pilot study to standardize clinical whole exome sequencing (WES) for cancer patients.
Menzel M, Ossowski S, Kral S, Metzger P, Horak P, Marienfeld R, Boerries M, Wolter S, Ball M, Neumann O, Armeanu-Ebinger S, Schroeder C, Matysiak U, Goldschmid H, Schipperges V, Fürstberger A, Allgäuer M, Eberhardt T, Niewöhner J, Blaumeiser A, Ploeger C, Haack TB, Tay TKY, Kelemen O, Pauli T, Kirchner M, Kluck K, Ott A, Renner M, Admard J, Gschwind A, Lassmann S, Kestler H, Fend F, Illert AL, Werner M, Möller P, Seufferlein TTW, Malek N, Schirmacher P, Fröhling S, Kazdal D, Budczies J, Stenzinger A. Menzel M, et al. Among authors: kirchner m. NPJ Precis Oncol. 2023 Oct 20;7(1):106. doi: 10.1038/s41698-023-00457-x. NPJ Precis Oncol. 2023. PMID: 37864096 Free PMC article.
Spatial profiling of the microenvironment reveals low intratumoral heterogeneity and STK11-associated immune evasion in therapy-naïve lung adenocarcinomas.
Goldschmid H, Kluck K, Ball M, Kirchner M, Allgäuer M, Winter H, Herth F, Heußel CP, Pullamsetti SS, Savai R, Yong TTK, Schirmacher P, Peters S, Thomas M, Christopoulos P, Budczies J, Stenzinger A, Kazdal D. Goldschmid H, et al. Among authors: kirchner m. Lung Cancer. 2023 Jun;180:107212. doi: 10.1016/j.lungcan.2023.107212. Epub 2023 Apr 23. Lung Cancer. 2023. PMID: 37141769
First proficiency testing for NGS-based and combined NGS- and FISH-based detection of FGFR2 fusions in intrahepatic cholangiocarcinoma.
Neumann O, Lehmann U, Bartels S, Pfarr N, Albrecht T, Ilm K, Christmann J, Volckmar AL, Goldschmid H, Kirchner M, Allgäuer M, Walker M, Kreipe H, Tannapfel A, Weichert W, Schirmacher P, Kazdal D, Stenzinger A. Neumann O, et al. Among authors: kirchner m. J Pathol Clin Res. 2023 Mar;9(2):100-107. doi: 10.1002/cjp2.308. Epub 2023 Jan 12. J Pathol Clin Res. 2023. PMID: 36635225 Free PMC article.
63 results